MedTrace Logo

Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis

NCT05840913 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-10-15

No results posted yet for this study

Summary

This is a randomized controlled trial comparing the anaesthetic efficacy of 1.8 and 3.6 mL of Articaine for inferior alveolar nerve block when treating mandibular molars with Irreversible Pulpitis

Conditions

  • Drug Effect
  • Pulpitis - Irreversible

Interventions

DRUG

Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge

Local anesthetic injection for intra- operative pain control

Sponsors & Collaborators

  • Armed Forces Institute of Dentistry, Pakistan

    lead OTHER

Principal Investigators

  • Kanza Zafar, BDS · AFID

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05840913 on ClinicalTrials.gov